The Obesity ETF SLIM
33.25 USD 0.00 (+0.00%)
Mar 12, 2020, 3:59 PM EDT
33.00 Day range 36.62
33.00 52-week range 43.40
News
marketbeat.com Corbus Pharmaceuticals Launches Phase 3 Cancer Trial, Teases More Obesity Drug Data Corbus Pharmaceuticals NASDAQ: CRBP has started a Phase 3 study of its cancer drug CRB-701 and expects an exploratory readout from a separate frontline combination study in the first quarter of next…
247wallst.com Obesity Pipeline vs. COVID Drag: The Hidden Numbers Deciding Pfizer's Q3 Fate on Nov. 3 Pfizer (NYSE:PFE | PFE Price Prediction) reports third-quarter results before the open on Tuesday, Nov. 3. Shares have gained 25% year to date.
globenewswire.com Corxel US and Amanat Acquisition Corp Announce Definitive Business Combination Agreement to Create Publicly Listed Obesity-Focused Biopharmaceutical Company BERKELEY HEIGHTS, N.J. and WESTFIELD, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Corxel Pharmaceuticals, Inc. (“Corxel US”), a clinical-stage biopharmaceutical company focused on developing innovative…
247wallst.com Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28 Viking Therapeutics (NASDAQ:VKTX | VKTX Price Prediction) reports third-quarter results on October 28, 2026. Shares fell 41.
globenewswire.com Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026 NORWOOD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that…
marketbeat.com Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances Rani Therapeutics NASDAQ: RANI outlined progress for its oral biologics delivery platform, including plans to advance its obesity program RT-114 and expectations for additional milestones from its…
zacks.com Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss Novo Nordisk's CagriSema delivers 25% weight loss in women, spotlighting three ETFs for diversified exposure to the sector's growth.
zacks.com Can Viking Therapeutics Carve Out a Place in the Obesity Market? VKTX advances oral VK2735 into phase III as it explores weight maintenance and faces intensifying obesity drug competition.
fool.com Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter. Multiple phase 3 trials for VK2735 are ongoing, with key results expected in 2027 to 2028. The company's future depends on VK2735's clinical success and ongoing pipeline development.
247wallst.com A $1,000 Investment in Eli Lilly Became $18,637. The Obesity Boom Changed Everything Eli Lilly spent most of its 150-year history as a quiet insulin maker before a single drug reshuffled the entire obesity market and turned a modest stake into a fortune that left the S&P 500 in the…
zacks.com Viking Therapeutics Starts Phase III Development of Obesity Pill VKTX launches two phase III studies of oral VK2735 for obesity, building on phase II results showing up to 12.2% mean weight loss.
prnewswire.com Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity SUNRISE -1 and SUNRISE-2 Studies to Evaluate Oral VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a…
globenewswire.com Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity -- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan…
fool.com Eli Lilly's Obesity Business Could Become a Much Bigger Healthcare Platform Eli Lilly (LLY -4.39%) is trying to turn blockbuster obesity drugs into something much bigger. Its path to $1,500 depends on whether new medicines, additional indications, manufacturing scale, and…
prnewswire.com Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity Study to Explore Oral Maintenance Dosing Regimens Following Initial Weight Loss with Subcutaneous VK2735 Monthly and Every-Other-Week Subcutaneous Regimens to also be Evaluated SAN DIEGO, Oct. 6,…
benzinga.com Novo Nordisk Says Next-Gen Obesity Drug Reduces Food Noise, Drives Weight Loss Novo Nordisk A/S (NYSE:NVO) on Wednesday revealed new clinical and real-world data at the 2026 European Association for the Study of Diabetes (EASD) Annual Meeting, showcasing the efficacy of its…
marketbeat.com Viking's Obesity Edge May Be Staying Power, Not Weight Loss Viking Therapeutics NASDAQ: VKTX stock jumped 36% on Sept. 22. The catalyst was new maintenance data for VK2735, its GLP-1/GIP obesity candidate, which showed that patients maintained most of their…
globenewswire.com Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks
247wallst.com Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about…
benzinga.com Weight Loss Drug: Viking Therapeutics Says Lead Obesity Drug Shows Weight Retention with Less Frequent Dosing Viking Therapeutics Inc. (NASDAQ:VKTX) stock surged on Tuesday after the company released positive topline results from its much-anticipated VK2735 maintenance trial.